大摩:药明康德去年盈利升逾倍 仍列为2026年首选
Zhi Tong Cai Jing·2026-01-13 06:37

Core Viewpoint - Morgan Stanley maintains WuXi AppTec (603259) as a top pick for 2026, setting a target price of 130 RMB for its A-shares and rating it as "Overweight" [1] Financial Performance - WuXi AppTec's revenue for 2025 is projected to increase by 15.8% to 45.5 billion RMB, while profit is expected to rise by 102.7% to 19.2 billion RMB [1] - Adjusted profit under non-IFRS standards is anticipated to grow by 41.3% to 15 billion RMB [1] Business Segments - Revenue from continuing operations is expected to grow by 21.4%, surpassing management's forecast of 17% to 18%, driven by strong performance in the chemical business and TIDES [1] - The company confirmed two significant one-time gains during the year, including approximately 1.4 billion RMB from the sale of its testing business [1]